BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY) and the Broad Institute Collaborate to Work on Unsuccessful Drugs


11/28/2012 9:10:20 AM

NUTLEY, NJ and CAMBRIDGE, MA – November 28, 2012 – Today, Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Translational and Clinical Research Center, and the Broad Institute announced a multi-year collaboration designed to identify novel indications for promising development-stage compounds using the Broad Institute's cutting-edge platforms of screening technologies. In a novel approach to create value for compounds that failed to meet critical phase 2 milestones or were otherwise halted for strategic reasons, Roche has prepared a collection of more than 300 compounds intended for diverse indications. Roche has made these compounds, collectively known as the Roche Repurposing Compound Collection (RRCC), available to the Broad Institute to identify alternative uses for patients. Financial terms of the agreement were not disclosed. The Broad Institute is well positioned to leverage its sophisticated toolbox of biological assays and disease expertise to uncover new therapeutic indications for Roche's high-quality compounds. By screening the entire RRCC, the Broad Institute will link advanced compounds to novel patient populations through common biochemical pathways. This approach is expected to reveal unique targets for new drug discovery projects. Additionally, novel disease associations may be found that will lead rapidly to new clinical evaluations in which the compounds have a higher probability of success.

"We look forward to collaborating with the Broad Institute to identify new uses for compounds in our RRCC," said Karen Lackey, Head, Medicinal Chemistry at Roche. "Over the last 20 years of drug discovery we have created many drug candidates that did not make it to market. By compiling these compounds into an annotated set and collaborating with the Broad Institute to put to use its technologies and disease expertise, we hope to discover ways to repurpose these compounds that will be beneficial for patients."

"The compounds in Roche's collection are compelling starting points: if we can find new applications for them, we may be able to accelerate the process of finding the right drug for the right patient," said Brian Hubbard, Director of the Broad Institute's Therapeutics Discovery and Development Platform. "In the course of this project, we will be using multiple, novel methods developed at the Broad Institute to identify these new therapeutic indications. By partnering with Roche, we hope to bring the benefits of these discoveries to patients."

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs ($9 billion US) in R&D. The Group posted sales of 42.5 billion Swiss francs ($47.8 billion US). Genentech, Inc. is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com. About the Broad Institute of MIT and Harvard The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community. Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to www.broadinstitute.org.

Hoffmann-La Roche Inc. 340 Kingsland Street

Nutley, New Jersey 07110-1199

Public Affairs Department

Contacts: Darien E. Wilson Haley Bridger Roche Broad Institute 973-562-2232 617-714-7968

Darien_e.wilson@roche.com hbridger@broadinstitute.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES